ABL Bio Inc. (KOSDAQ:298380)

Splunk Statistics

Total Valuation

ABL Bio has a market cap or net worth of KRW 4.04 trillion. The enterprise value is 3.98 trillion.

Market Cap	4.04T
Enterprise Value	3.98T

Important Dates

The next estimated earnings date is Monday, August 11, 2025.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

ABL Bio has 54.58 million shares outstanding. The number of shares has increased by 0.57% in one year.

Current Share Class	54.58M
Shares Outstanding	54.58M
Shares Change (YoY)	+0.57%
Shares Change (QoQ)	+0.37%
Owned by Insiders (%)	26.59%
Owned by Institutions (%)	16.25%
Float	40.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	123.95
PS Ratio	146.36
PB Ratio	28.27
P/TBV Ratio	29.45
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-55.53
EV / Sales	144.10
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-42.11

Financial Position

The company has a current ratio of 1.70, with a Debt / Equity ratio of 0.30.

Current Ratio	1.70
Quick Ratio	1.67
Debt / Equity	0.30
Debt / EBITDA	n/a
Debt / FCF	-0.46
Interest Coverage	-2,445.09

Financial Efficiency

Return on equity (ROE) is -69.33% and return on invested capital (ROIC) is -31.54%.

Return on Equity (ROE)	-69.33%
Return on Assets (ROA)	-26.36%
Return on Invested Capital (ROIC)	-31.54%
Return on Capital Employed (ROCE)	-51.25%
Revenue Per Employee	270.89M
Profits Per Employee	-703.00M
Employee Count	102
Asset Turnover	0.16
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +173.43% in the last 52 weeks. The beta is 0.77, so ABL Bio's price volatility has been lower than the market average.

Beta (5Y)	0.77
52-Week Price Change	+173.43%
50-Day Moving Average	72,784.00
200-Day Moving Average	49,073.75
Relative Strength Index (RSI)	50.99
Average Volume (20 Days)	1,233,003

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABL Bio had revenue of KRW 27.63 billion and -71.71 billion in losses. Loss per share was -1,489.50.

Revenue	27.63B
Gross Profit	27.58B
Operating Income	-74.13B
Pretax Income	-71.71B
Net Income	-71.71B
EBITDA	-71.78B
EBIT	-74.13B
Loss Per Share	-1,489.50

Balance Sheet

The company has 108.57 billion in cash and 43.34 billion in debt, giving a net cash position of 65.22 billion or 1,195.12 per share.

Cash & Cash Equivalents	108.57B
Total Debt	43.34B
Net Cash	65.22B
Net Cash Per Share	1,195.12
Equity (Book Value)	143.03B
Book Value Per Share	2,887.92
Working Capital	46.51B

Cash Flow

In the last 12 months, operating cash flow was -80.25 billion and capital expenditures -14.32 billion, giving a free cash flow of -94.57 billion.

Operating Cash Flow	-80.25B
Capital Expenditures	-14.32B
Free Cash Flow	-94.57B
FCF Per Share	-1,732.76

Margins

Gross margin is 99.81%, with operating and profit margins of -268.30% and -259.52%.

Gross Margin	99.81%
Operating Margin	-268.30%
Pretax Margin	-259.52%
Profit Margin	-259.52%
EBITDA Margin	-259.79%
EBIT Margin	-268.30%
FCF Margin	n/a

Dividends & Yields

ABL Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.57%
Shareholder Yield	n/a
Earnings Yield	-1.77%
FCF Yield	-2.34%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABL Bio has an Altman Z-Score of 9.49.

Altman Z-Score	9.49
Piotroski F-Score	n/a